ClinicalTrials.gg
CompletedNCT04937153Updated Jul 16, 2025

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

A Phase 1 interventional study of Acasunlimab and Pembrolizumab in Solid Tumor, sponsored by Genmab. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Genmab · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must have a -confirmed non-central nervous system (CNS) solid tumor that is or unresectable and for whom there is no available standard therapy likely to confer clinical benefit; or a participant who is not a candidate for such available therapy and for whom, in the opinion of the investigator, experimental therapy with acasunlimab or acasunlimab in combination with pembrolizumab may be beneficial.
  • Asian race and Japanese ethnicity.
  • Have according to (RECIST) 1.1.
  • Have (ECOG) 0-1.
  • Have an acceptable hematological status.
  • Have acceptable liver function.
  • Have an acceptable coagulation status.
  • Have acceptable renal function.
  • Should provide a tumor tissue sample (formalin-fixed paraffin-embedded [FFPE] blocks/slides) from or fresh biopsy collected before C1D1, preferably derived from advanced disease stage.

Key Exclusion Criteria:

  • Have uncontrolled intercurrent illness, including but not limited to:

    • Ongoing or active infection requiring intravenous treatment with anti-infective therapy, or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
    • Symptomatic congestive heart failure (Grade III or IV as classified by the ), unstable angina pectoris or cardiac arrhythmia.
    • Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management.
    • Ongoing or recent evidence of disease.
    • History of irAEs that led to prior checkpoint treatment discontinuation.
    • Prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
    • History of chronic liver disease or evidence of hepatic cirrhosis.
    • Evidence of interstitial lung disease.
    • History of non-infectious pneumonitis that has required or currently has pneumonitis.
    • History of organ allograft (except for corneal transplant) or or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of trial treatment.
    • Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive or stroke.
  • Prior therapy:

    • Radiotherapy: Radiotherapy within 14 days prior to the first dose of trial treatment. Palliative radiotherapy will be allowed.
    • Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to trial treatment administration.
  • Toxicities from previous anti-cancer therapies that have not adequately resolved.

Note: Other protocol specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    acasunlimab monotherapy

    Biological: Acasunlimab

  • Experimental
    acasunlimab + pembrolizumab combination therapy

    Biological: Acasunlimab · Biological: Pembrolizumab

Interventions

  • BiologicalAcasunlimab

    Acasunlimab will be administered intravenously (IV) once every 21 days.

    Also known as: GEN1046, DuoBody®-PD-L1x4-1BB

  • BiologicalPembrolizumab

    Pembrolizumab will be administered IV once every 21 days.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose limiting Toxicities (DLTs)

    Determine the DLT profile of acasunlimab administered as monotherapy or in combination with pembrolizumab. The DLTs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.

    Time frame: During first cycle (Cycle length=21 days) in each cohort

  2. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From first dose date up to end of the safety follow up period, 90 days after last dose

  3. Area under the concentration time curve (AUC) of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

  4. Maximum (Peak) Plasma Concentration (Cmax) of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

  5. Time to Reach Cmax (Tmax) of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

  6. Plasma Trough (Pre-dose) Concentrations (Cthrough) of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

  7. Elimination half-life (t 1/2) of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)

Secondary outcomes

  1. Number of Participants with Anti-Drug Antibody (ADA) to Acasunlimab

    Serum samples will be screened for ADAs to acasunlimab and the titer of confirmed positive samples will be reported.

    Time frame: Up to 2 years

07

Study locations

2 sites
  • National Cancer Center East
    Chiba, Japan
  • National Cancer Center Hospital
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Oct 2024, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
Jun 23, 2021
StartActual
Jun 15, 2021
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 1, 2024
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04937153
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jun 15, 2021
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Last update
Jul 16, 2025

Study contacts

Study Official
study director · Genmab

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acasunlimab

Start the discussion